FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic communications environment.
Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.
Dan Chichester, chief creative officer, LLNS
When you have a successful brand, you tamper with it at your peril
We cemented our credibility during the most difficult period for publishing
Stuart Raetzman, CEO, Galderma Labs
Linzess has been enhanced and reworked to reach self-identified sufferers with its own brand relief story
What happens when it's the FDA—not a medical marketer—that is doing the overstating?
Don't waste another minute or dollar on your brand standards manual. It's painfully irrelevant